Skip to main content
LYSOGENE logo

LYSOGENE — Investor Relations & Filings

Ticker · LYS ISIN · FR0013233475 LEI · 969500T64RILK1RD0852 PA Professional, scientific and technical activities
Open in API
Filings indexed 254 across all filing types
Latest filing 2021-11-26 Capital/Financing Update
Country FR France
Listing PA LYS

About LYSOGENE

https://www.lysogene.com

Lysogene was a clinical-stage biotechnology company that specialized in the research and development of gene therapies for rare, inherited neurodegenerative diseases affecting the central nervous system (CNS). The company's approach focused on delivering a functional copy of a deficient gene directly to the brain to address the root cause of the targeted disorder. Its pipeline included investigational treatments for lysosomal storage diseases such as Sanfilippo syndrome type A (MPS IIIA) and GM1 gangliosidosis. Following clinical and financial challenges, the company initiated judicial liquidation proceedings in 2023.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Capital/Financing Update Classification · 1% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and announces that Lysogene has obtained non-dilutive financing of 4.3 million euros from Bpifrance. This announcement details fundraising activities, loan structures (R&D innovation loan and recoverable advance), and its impact on cash visibility and program development. This content directly aligns with the definition of 'Capital/Financing Update' (CAP), which covers company fundraising and financing activities. It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it pertains to a specific financing event.
2021-11-26 French
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is explicitly titled "PRESS RELEASE" and announces that Lysogene will present data on its LYS-GM101 program at the ESGCT 2021 Annual Virtual Conference. This is not a full financial report (like 10-K or IR), nor is it a transcript (CT) or a formal regulatory filing detailing results (ER/AR). It is an announcement about an upcoming presentation of scientific/clinical data. This fits best under the category of Investor Presentation (IP) if it were the presentation itself, but since it is an announcement *about* a presentation, and it is a general press release format, it is most closely aligned with a Regulatory Filing (RNS) as a general corporate update, or potentially an Investor Presentation (IP) if the content is highly focused on investment-relevant data, which it is (clinical trial status). Given the context of presenting clinical/preclinical results at a conference, 'Investor Presentation' (IP) is a strong candidate, but since it's a press release *announcing* the presentation, and not the presentation material itself, 'Regulatory Filings' (RNS) serves as the appropriate general announcement category when a more specific category like 'RPA' (Report Publication Announcement) doesn't perfectly fit the nature of the announcement (which is about a presentation, not a formal financial report publication). However, looking closely at the definitions, this is a standard corporate communication about upcoming investor/scientific engagement. Since it's not a formal financial report announcement (RPA) or a specific management/board change (MANG), and it details clinical progress which is key investor information, I will classify it as an Investor Presentation (IP) announcement, or RNS if IP is too specific for an announcement *of* a presentation. Given the options, RNS is the safest fallback for a general press release about scientific updates, but IP covers the *subject matter*. Since the document is short and announces an event where an IP would be given, RNS is the most appropriate general regulatory announcement category here, as it is not announcing the release of a formal report (RPA). I will lean towards RNS as the best fit for a general press release announcing participation in a conference.
2021-10-18 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is titled 'COMMUNIQUE DE PRESSE' (Press Release) and announces that Lysogene will make an oral presentation about its drug candidate LYS-GM101 at the ESGCT 2021 conference. It details the presenter, the date/time of the presentation, and includes quotes about preclinical results. This is not a full financial report (10-K, IR), an earnings release (ER), or a formal regulatory filing like a proxy statement. It is an announcement regarding participation in an investor/scientific event, which often falls under Investor Presentation (IP) if it were the presentation itself, or a general announcement. Given the content focuses on scientific/clinical updates being presented at a conference, 'Investor Presentation' (IP) is the closest fit for the *subject matter* being announced, although the document itself is a press release announcing the presentation. However, since the document is a press release announcing a presentation of scientific/clinical data, and it is not a formal financial report, 'Investor Presentation' (IP) is the most appropriate category for the *type of information* being disseminated, as these press releases often precede or accompany investor-facing materials. If 'RPA' (Report Publication Announcement) were used, it would imply the announcement of a formal report (like an Annual Report), which this is not. Therefore, classifying it as an announcement related to investor information/presentation material is best.
2021-10-18 French
Quarterly financial reporting / Third quarter financial report
Earnings Release Classification · 1% confidence The document is explicitly titled "PRESS RELEASE" and reports the company's "Cash Position as of 30 September 2021." This format, focusing on key financial highlights (cash balance, comparison to the previous quarter) released shortly after the period end (October 8, 2021, for Q3 2021 data), strongly indicates an Earnings Release (ER). It is not a comprehensive Annual Report (10-K) or a detailed Interim Report (IR), nor is it a transcript (CT) or a presentation (IP). It serves as the initial announcement of period results. FY 2021
2021-10-08 English
Information financière trimestrielle / Information financière du troisième trimestre
Earnings Release Classification · 1% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and its primary content is the announcement of the company's cash position as of September 30, 2021, comparing it to the previous quarter (June 30, 2021). This format, focusing on key financial highlights for a specific period (quarterly cash position), strongly aligns with an Earnings Release (ER), which typically provides the initial announcement of periodical financial results. It is not a full Annual Report (10-K) or a comprehensive Interim Report (IR) as it only provides a single key metric (cash position) and not the full balance sheet, income statement, or cash flow statement. It is too specific to be a general Regulatory Filing (RNS) and does not fit the definitions for other specialized reports like Audit Reports (AR), Management Discussion (MDA), or Investor Presentations (IP). Therefore, the most appropriate classification is Earnings Release (ER). 9M 2021
2021-10-08 French
Inside Information / News release on accounts, results
Earnings Release Classification · 1% confidence The document is explicitly titled "PRESS RELEASE" and announces the company's "Financial Results for the first half 2021" along with an operational update. It contains selected financial information (Income statement, Net cash) for the six months ended June 30, 2021, and discusses business progress (clinical trials, licensing). This structure—a press release summarizing period-specific financial performance—is the hallmark of an Earnings Release (ER). It is not the full, audited Annual Report (10-K) nor the comprehensive Interim/Quarterly Report (IR), as it is presented as a high-level summary announcement, and it specifically mentions the next financial release date, confirming this is the initial results announcement. H1 2021
2021-09-24 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.